Fresh analysis suggests that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight far faster than those who stop conventional diet and exercise plans.
Findings released in a major health publication demonstrates that while obese people often shed a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying these medications need to be aware of the potential of fast weight regain when the medication concludes," stated researcher Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment mass in about a year and a half.
Weighing Therapies
The study, which examined dozens of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers note that people who lose weight through dieting generally have a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors believe the mechanism of the jabs accounts for the amplified weight return.
The injections mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, due to the significant potential of relapse, the therapy might need to be long-term.
This view is reinforced by drug manufacturers, who note that the results "emphasize the long-term nature of obesity," similar to managing diseases like diabetes.
User Accounts
People who have come off the medication describe a sudden resurgence of cravings.
"It was like something activating and you become starving," said an individual.
This challenge is worsened if patients have not established permanent dietary or behavioural changes during therapy.
Growing Interest
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic solution and maintained weight loss relies on integrated lifestyle changes.
